For research and educational purposes only. Not medical advice.
Selegiline Reference
Educational, not medical advice reference for Selegiline: Nootropic, Cognitive; regulatory status, evidence posture, source review, and schedule notes. Also…
Reference summary
Selegiline is label-verified for Parkinson's and MDD. Off-label longevity / cognitive use literature is older (Knoll et al.) and small.
- Categories
- Nootropic, Cognitive
- Aliases
- Deprenyl, L-Deprenyl, Eldepryl, Emsam, Zelapar
- Evidence posture
- human — FDA-approved for Parkinson's disease and MDD. Off-label nootropic / longevity micro-dosing is outside the FDA label. MAO-B inhibition becomes non-selective at higher doses; tyramine-containing foods (aged cheeses, cured meats) can produce hypertensive crises at non-selective doses. Concomitant SSRIs / serotonergic agents can produce serotonin syndrome.
- Regulatory status
- FDA-approved prescription medication. Eldepryl / Zelapar are oral selegiline approved as adjunctive Parkinson's disease therapy. Emsam is a transdermal selegiline approved for major depressive disorder. Off-label nootropic micro-dosing is outside the FDA label and may interact dangerously with tyramine-containing foods (Emsam transdermal at higher doses requires dietary restriction) and serotonergic agents.
- Content review status
- label verified